• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adjuvant Immunotherapy Should Be Used in Patients With Non-Small Cell Carcinoma With a Pathologic Complete Response to Neoadjuvant Immunotherapy.

作者信息

Uprety Dipesh, Roden Anja C, Peters Solange

机构信息

Department of Medical Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

出版信息

J Thorac Oncol. 2025 Jan;20(1):34-38. doi: 10.1016/j.jtho.2024.11.004.

DOI:10.1016/j.jtho.2024.11.004
PMID:39794104
Abstract
摘要

相似文献

1
Adjuvant Immunotherapy Should Be Used in Patients With Non-Small Cell Carcinoma With a Pathologic Complete Response to Neoadjuvant Immunotherapy.辅助免疫疗法应用于对新辅助免疫疗法有病理完全缓解的非小细胞癌患者。
J Thorac Oncol. 2025 Jan;20(1):34-38. doi: 10.1016/j.jtho.2024.11.004.
2
Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.新辅助免疫治疗局部晚期可切除非小细胞肺癌：系统评价和荟萃分析。
Cancer. 2023 Jul 1;129(13):1969-1985. doi: 10.1002/cncr.34755. Epub 2023 Mar 30.
3
Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World).可切除非小细胞肺癌患者接受新辅助免疫化疗的治疗模式和临床结局：一项大规模、多中心、真实世界研究（NeoR-World）。
J Thorac Cardiovasc Surg. 2024 Oct;168(4):1245-1258.e17. doi: 10.1016/j.jtcvs.2024.02.006. Epub 2024 Feb 10.
4
The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis.围手术期免疫治疗非小细胞肺癌的价值：荟萃分析。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241258164. doi: 10.1177/15330338241258164.
5
Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.新辅助-辅助与新辅助单药 PD-1/PD-L1 抑制剂治疗可切除 NSCLC 患者的疗效比较：一项间接荟萃分析。
JAMA Netw Open. 2024 Mar 4;7(3):e241285. doi: 10.1001/jamanetworkopen.2024.1285.
6
Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer.基于免疫治疗的新辅助治疗在可切除非小细胞肺癌中的真实世界结局。
Front Immunol. 2023 Sep 25;14:1268251. doi: 10.3389/fimmu.2023.1268251. eCollection 2023.
7
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.新辅助化疗免疫治疗后可切除非小细胞肺癌患者完全或主要病理缓解后的无事件生存期改善，无论辅助治疗如何：一项系统评价和个体患者数据荟萃分析
J Thorac Oncol. 2025 Mar;20(3):285-295. doi: 10.1016/j.jtho.2024.09.1443. Epub 2024 Oct 9.
8
Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis.非小细胞肺癌新辅助免疫治疗和化疗的短期疗效：一项系统评价和荟萃分析。
JTCVS Open. 2021 Sep 2;8:588-607. doi: 10.1016/j.xjon.2021.08.036. eCollection 2021 Dec.
9
Adjuvant immunotherapy does not improve survival in non-small cell lung cancer with major/complete pathologic response after induction immunotherapy.辅助免疫疗法并不能改善诱导免疫疗法后出现主要/完全病理缓解的非小细胞肺癌患者的生存率。
J Thorac Cardiovasc Surg. 2025 Jun;169(6):1576-1584.e3. doi: 10.1016/j.jtcvs.2024.11.028. Epub 2024 Nov 29.
10
Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.可切除非小细胞肺癌新辅助治疗中免疫治疗的现状和未来展望。
Asia Pac J Clin Oncol. 2022 Aug;18(4):335-343. doi: 10.1111/ajco.13665. Epub 2021 Nov 23.

引用本文的文献

1
Efficacy of adjuvant therapy regimens administered during the perioperative period in resectable non-small cell lung cancer.可切除非小细胞肺癌围手术期辅助治疗方案的疗效
Cancer Immunol Immunother. 2025 Sep 1;74(9):296. doi: 10.1007/s00262-025-04159-0.
2
Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study.可切除的 III 期非小细胞肺癌患者在新辅助化疗免疫治疗后辅助免疫治疗是否必要？一项双中心真实世界研究。
Cancer Immunol Immunother. 2025 Jul 21;74(8):273. doi: 10.1007/s00262-025-04130-z.
3
Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy.
免疫治疗时代非小细胞肺癌的围手术期管理
Cells. 2025 Jun 25;14(13):971. doi: 10.3390/cells14130971.